Phathom Pharmaceuticals (PHAT) PT Raised to $29 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts PHAT Hot Sheet
Price: $5.74 -18.12%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Cantor Fitzgerald analyst Kristen Kluska raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $29.00 (from $23.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- Graphano Energy amends private placement to add flow-through shares
- Howard Hughes Holdings to join S&P SmallCap 600 on Oct. 28
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor Fitzgerald, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
